4,791 Shares in Amgen Inc. (NASDAQ:AMGN) Acquired by Natural Investments LLC

Natural Investments LLC bought a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 4,791 shares of the medical research company's stock, valued at approximately $1,248,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Unionview LLC lifted its holdings in shares of Amgen by 3.8% in the third quarter. Unionview LLC now owns 876 shares of the medical research company's stock worth $282,000 after buying an additional 32 shares in the last quarter. Semus Wealth Partners LLC increased its position in Amgen by 2.3% in the third quarter. Semus Wealth Partners LLC now owns 1,531 shares of the medical research company's stock worth $493,000 after purchasing an additional 35 shares during the last quarter. Connable Office Inc. increased its position in Amgen by 0.5% in the third quarter. Connable Office Inc. now owns 6,972 shares of the medical research company's stock worth $2,246,000 after purchasing an additional 37 shares during the last quarter. Blossom Wealth Management increased its position in Amgen by 3.5% in the fourth quarter. Blossom Wealth Management now owns 1,090 shares of the medical research company's stock worth $284,000 after purchasing an additional 37 shares during the last quarter. Finally, Zullo Investment Group Inc. increased its position in Amgen by 2.8% in the fourth quarter. Zullo Investment Group Inc. now owns 1,364 shares of the medical research company's stock worth $356,000 after purchasing an additional 37 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Amgen

In other Amgen news, EVP Murdo Gordon sold 8,771 shares of the company's stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $294.79, for a total value of $2,585,603.09. Following the sale, the executive vice president now owns 44,186 shares of the company's stock, valued at approximately $13,025,590.94. This represents a 16.56 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Nancy A. Grygiel sold 1,589 shares of the company's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the sale, the senior vice president now directly owns 7,210 shares in the company, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 69,341 shares of company stock worth $20,644,335. 0.69% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on AMGN. Truist Financial cut their price objective on shares of Amgen from $333.00 to $298.00 and set a "hold" rating on the stock in a research report on Wednesday, January 8th. Piper Sandler Companies reiterated an "overweight" rating and set a $310.00 price objective on shares of Amgen in a research report on Thursday, January 2nd. Redburn Partners cut their price target on shares of Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. UBS Group restated a "hold" rating on shares of Amgen in a report on Wednesday, February 12th. Finally, Deutsche Bank Aktiengesellschaft cut their price target on shares of Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $314.04.

Remove Ads

Amgen Stock Performance

Shares of AMGN opened at $327.36 on Tuesday. The stock has a 50-day simple moving average of $287.50 and a 200-day simple moving average of $299.50. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The stock has a market capitalization of $175.86 billion, a PE ratio of 43.36, a PEG ratio of 2.63 and a beta of 0.53. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 2.91%. The ex-dividend date is Friday, May 16th. Amgen's dividend payout ratio is currently 126.09%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.